Celcuity (CELC) has drawn investor attention after recent trading that left the stock around $138.23, supported by a clinical stage pipeline focused on targeted therapies for solid tumors.

The share price has cooled slightly in the last day, with a 1 day share price return showing a 3.02% decline. Momentum over longer periods remains strong, including a 30 day share price return of 14.21% and a very large 1 year total shareholder return that is above 10x.

If the recent move in Celcuity has you thinking about where else growth might emerge in healthcare, it can be useful to scan 34 healthcare AI stocks

With Celcuity now valued around $6.7b and trading at $138.23, along with a very large 1-year total return and an implied discount to analyst targets, is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 18.4% Overvalued

Celcuity's widely followed narrative sets a fair value of $116.70, which sits below the recent $138.23 close, highlighting how much optimism is already priced in.

Management estimates a US$5b to US$6b addressable market in second line HR positive, HER2 negative advanced breast cancer and has indicated potential peak revenue for gedatolisib of US$2.5b to US$3b in this setting. If partially realized, this would be a key driver of top line growth over time.

Want to see what turns that huge market estimate into a specific fair value per share? The narrative leans heavily on projected revenue build, margin expansion and a premium future earnings multiple. Curious which combination of those assumptions really drives the $116.70 figure and the 18.4% overvaluation signal?

Result: Fair Value of $116.70 (OVERVALUED)

However, the story can change quickly if gedatolisib data disappoints or if approval timelines slip, which could stretch current losses and test the balance sheet.

Another View: DCF Points the Other Way

The narrative based on analyst targets suggests Celcuity trades above a fair value of $116.70, but the SWS DCF model tells a very different story, with an estimated value of $832.92 per share. That is a very large gap. Which set of assumptions do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celcuity for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such a mixed picture on valuation and future outcomes, it makes sense to review the underlying data yourself and form a clear view quickly. To frame that view, weigh up the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Celcuity has sharpened your focus, now is the moment to broaden your watchlist with fresh, high conviction ideas sourced from structured screeners.

• Spot potential standouts early by checking screener containing 21 high quality undiscovered gems before they attract wider attention.
• Protect your downside by focusing on companies highlighted in the 67 resilient stocks with low risk scores so your portfolio is not built only around higher volatility stories.
• Build a sturdier core by using the solid balance sheet and fundamentals stocks screener (46 results) to find businesses with financial footing that can support long term plans.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.